Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia

Transfusion-related complications and lack of resources in low-to-middle-income countries have led to a search for novel therapies to reduce the need for blood transfusions in patients with β-thalassemia. Hydroxyurea (HU) has demonstrated promising outcomes; additionally, thalidomide has also shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Saqib H., Ansari, Iqra, Wasim, Misbah, Sattar, Amjad, Khawaja, Shariqa, Zohaib, Muhammad, Hussain, Zeeshan, Adil, Syed Omair, Ansari, Ali H., Ansari, Usman H., Farooq, Fawad, Masqati, Noor-un-Nisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772794/
https://www.ncbi.nlm.nih.gov/pubmed/35477175
http://dx.doi.org/10.1182/bloodadvances.2022007031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772794/
https://www.ncbi.nlm.nih.gov/pubmed/35477175
http://dx.doi.org/10.1182/bloodadvances.2022007031

Ejemplares similares